The abstract is read at the publisher; the summary is JClub's.
CDK4/6 inhibitors have transformed treatment of patients with breast cancer, with regulatory approval limited to this setting despite a decade of research.
- Why it matters: The gap is that CDK inhibitor clinical use has not yet expanded beyond breast cancer, even as new studies suggest opportunities in other tumor types.
- What they did: This Review summarizes changes in clinical use since the first FDA approval 10 years ago, focusing on new combinatorial strategies with HER2 and PI3K inhibitors, resistance insights, and biomarker efforts.
- The result: Emerging approaches—including selective CDK2 inhibitors for refractory disease and next-generation CDK4-selective inhibitors to mitigate hematological toxicity—suggest broader cancer potential, though biomarkers remain underdeveloped clinically.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.